Table 2.
Outcomes Among Patients Receiving Anticoagulation for VTE
| Characteristic | Values | p-value |
|---|---|---|
| Thrombosis progression | No (%) of patients | |
| Catheter-associated thrombosis progression | 2 (3) | |
| DVT/PE progression | 2 (11) | |
| Pulmonary embolism | 3 (4) | |
| Mortality | No (%) of patients | |
| Death within 90 days | 17 (21) | |
| Bleeding Outcomes | No (%) of patients | |
| Events (total) | 31 (37) | |
| Grade 2 | 22 (71) | |
| Grade 3 | 5 (16) | |
| Grade 4 | 4 (13) | |
| Events (in the absence of anticoagulation) | 4 (5) | |
| Grade 2 | 4 (100) | |
| Grade 3 | 0 | |
| Grade 4 | 0 | |
| Degree of thrombocytopenia | Platelets x109/L, range (median) | |
| At time of bleed | 8–518 (54) | |
| Grade 2 | 25–518 (52.5) | |
| Grade 3/4 | 8–403 (54) | p = 0.516* |
| Mean 30 day platelet count, range | ||
| No bleeding | 14–283 (73) | |
| Grade 2 | 32–124 (57) | |
| Grade 3/4 | 48–275 (80) | p = 0.074* |
| Duration of Thrombocytopenia | Days, range (median) | |
| Days with morning platelet count <50, range (median) | ||
| No bleeding, range (median) | 0–24 (4.5) | |
| Grade 2, range (median) | 2–30 (8) | |
| Grade 3/4, range (median) | 1–12 (4) | p = 0.020* |
*
All p-values are the result of ANOVA comparisons between the no-bleeding, grade 2 bleeding and grade ¾ bleeding groups.